Abstract 1008: Prevalence of FoxM1 expression in Middle Eastern epithelial ovarian carcinoma patients and its potential role as a therapeutic target

FoxM1 is a member of Forkhead transcription factors and its expression has been found to be altered in a variety of cancers. Several studies have indicated the importance of FoxM1 in cell proliferation, as it is a key cell-cycle regulator of both the transition from G1 to S phase and the progression to mitosis. In this study, we investigated the functional consequences of FoxM1 signaling pathway in a large cohort of epithelial ovarian cancer (EOC) tumor (patient) samples, panel of cell lines, and in nude mouse model. Using immunohistochemistry, FoxM1 was detected in 47.4% (64/135) of the ovarian tumor samples. EOC with FOX-M1 expression showed a significantly better disease free survival(p=0.0148) of 21.9 months as compared to the EOC with low FOX-M1 expression(14.4 months). Overexpression of FoxM1 was also significantly associated with activated p-AKT(p=0.0072), SKP2(p=0.0121), p-Rb(p=0.0357), UBE2C(p=0.0106), FAS-N(p=0.0179), PIK3CA p110αIHC(p=0.0362), XIAP(p=0.0033) and tumor proliferative marker Ki167 (p